Nippon Chemiphar Co., Ltd. · TSE:4539
Nippon Chemiphar — FY2007 Earnings Presentation
11 slides from Nippon Chemiphar's earnings presentation, May 20, 2008
Slide 1: Highlights of Business Results
2008/6/13 Highlights of Business Results (Year ending March 31, 2008) Mayy 20,, 2008 Nippon Chemiphar Co., Ltd. 4539 2 2 Contents Slides Consolidated, Non-Consolidated Sales and Income 3, 4 Non-Consolidated Sales and Operating p g Income 5,, 6 Core Products, Generics : Sales and Forecasts 7, 8 Gener
Slide 2: Consolidated and Non-Consolidated Sales and Income
2008/6/13 3 Consolidated Sales, Income ¥mn FY2006 FY2007 FY2008 (Forecast) Distrib. Distrib Distrib. Distrib YOY Distrib. Distrib YOY Amount Amount Amount (%) (%) (%) (%) (%) Sales 20,966 100.0 20,918 100.0 (0.2) 23,900 100.0 14.3 Excluding WL* 20,208 20,918 3.5 Operating 1,395 6.7 1,170 5.6 (16.1)
Slide 3: Non-Consolidated Sales and Operating Income
2008/6/13 5 Non-Consolidated Sales Up 4% YOY Up 5% YOY ¥mn 24,000 23,000 Up 4% YOY Up15% YOY 22,000 20,000 Down 2% YOY 19,823 19,072 18,000 18,358 17,538 16,000 15,274 Up16% YOY 15,663 , 14,000 12,000 10,000 (FY) 2002 2003 2004 2005 2006 2007 2008 (Forecast) 6 Non-Consolidated Operating Income ¥mn 1
Slide 4: Sales of Core Products and Generics, Forecasts
2008/6/13 7 Sales of Core Products, Forecasts ¥mn FY2006 FY2007 FY2008 Forecast Distrib. Distrib. YOY YOY Distrib. YOY YOY Amount Amount Amount (%) (%) (Amount) (%) (%) (Amount) (%) Uralyt 3,083 3,474 391 12.7 3,650 176 Soleton 4,097 3,957 (140) (3.4) 3,750 (207) Calvan 779 724 (55) (7.1) 700 (24) C
Slide 5: Sales of Generics and Forecasts for FY2008
2008/6/13 9 Sales of Generics Up 7.4% YOY ¥bn Up 18.7% YOY 14 Up 15.0% YOY 12 13.00 10 Up 29.2% YOY 9.68 9.01 8 7.84 Up 15.5% YOY 6.60 6 5.06 4 38 4.38 Up 34.3% YOY 4 2 0 (FY) 2002 2003 2004 2005 2006 2007 2008 (Forecast) 10 Forecasts for FY2008 ¥bn Core Products Generic Products FY2007 8.16 9.68 3.
Slide 6: Enhancement of Generics Lineup; Support for DPC Hospitals
2008/6/13 11 Enhancement of Generics Lineup FY2008 FY2006 FY2007 (Forecast) New Products 12 16 18 Planned FY2008 total: 148 products. Amlodipine-Chemiphar will be launched in July 2008 Original pharmaceuticals: Norvasc (Phizer), Amulodine (Dainippon Sumitomo Pharma) 12 Support for DPC* Hospitals Co-
Slide 7: Generics Sales to DPC Hospitals
2008/6/13 13 Generics Sales to DPC Hospitals (%) ? 250 211.3 197.9 200 182.1 151.8 150 100.0 104.4 100 50 0 (FY) 1st half 2005 2nd half 2005 1st half 2006 2nd half 2006 1st half 2007 2nd half 2007 14 Use of Chemiphar Products in Public Hospitals All Products Generic Pharmaceuticals 100 80 92.1 89.4
Slide 8: Generics Sales to Dispensing Pharmacies
2008/6/13 15 Generics Sales to Dispensing Pharmacies (%) ? 170 160 161.1 150 143.9 145.3 140 134.4 130 120 110 112.5 100.0 100 (FY) 1st half 2nd half 1st half 2nd half 1st half 2nd half 2005 2005 2006 2006 2007 2007 16 Sales to Top 100 Dispensing Pharmacy Chains (%) Sales Generic sales 200 173.1 154
Slide 9: FY2008 Operating Income Forecast; Drivers to Expand Generics Market 1
2008/6/13 17 FY2008 Operating Income Forecast (¥bn) FY2008 FY2009 Mid-Term FY2008 Mid-Term Change Management Forecast Management Plan Plan Sales 24.5 23.9 (0.6) 28.0 Sales of generics 13.5 13.0 (0.5) 16.6 Operating income 1.8 1.4 (0.4) 2.32 Operating income ratio 7.3% 5.9% (1.4P) 8.3% Reasons for de
Slide 10: Drivers to Expand Generics Market 2 and 3
2008/6/13 19 Drivers to Expand Generics Market 2 Government steps to expand generics market Further F th iincentives ti for f dispensing di i pharmacies. h i New prescription form. Points system for dispensing generics. Pharmacists obliged to explain, promote generics to patients. Makers required to
Slide 11: Note about Forward-Looking Statements and Forecasts
2008/6/13 21 Note about Forward-Looking Statements and Forecasts Statements made in this highlights of business results with respect to current plans, estimates, strategies and beliefs, and other statements of Nippon Chemiphar that are not historical facts are forward-looking statements about the fu